Business · 30/04/2014
FDA Announces Opportunity for Hearing on Proposal to Revoke Allergy Laboratories' Biologics License
The FDA is seeking public input on a proposal to revoke Allergy Laboratories' license for a nonstandardized allergenic extract, citing a lack of scientific evidence supporting its safety and effectiveness.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →